Bepanthenol Sensiderm Bayer Cream 20g
- Brand: BAYER SpA
- Product Code: 924995057
- EAN: 8000560990188
- Availability: In Stock
- Purchase 3 items for 10.12€ each
- Purchase 4 items for 9.92€ each
- Purchase 5 items for 9.71€ each
Bepanthenol Sensiderm Bayer Cream - Medical Device Without Cortisone
With a moisturizing and protective action, it gives quick relief from itching and redness caused by dermatitis and other skin irritations.
Bepanthenol® Sensiderm is a cortisone-free cream that acts on the symptoms of dermatitis by preventing the entry of irritants.
Thanks to lamellar lipids , in fact, Bepanthenol® Sensiderm Cream helps restore the skin barrier by integrating the missing lipids and thus relieving itching. Furthermore, thanks to dexpanthenol , glycerin and other humectant components , it moisturizes the skin and promotes its regeneration.
Bepanthenol® Sensiderm Cream is a product for the whole family : it does not contain perfume, parabens or preservatives.
Practicality
Bepanthenol® Sensiderm cream :
- It is free of cortisone.
- It can also be used several times a day.
- It does not contain emulsifiers.
- It is free from fragrances, preservatives, parabens and other potentially allergenic substances.
- It is suitable for the whole family, even for children and infants.
- It is suitable for use during pregnancy and while breastfeeding.
Ingrediants
Bepanthenol® Sensiderm cream contains:
Lamellar lipids (e.g. ceramides): help restore the damaged skin barrier. In fact, the lipids arranged in lamellae integrate into the damaged stratum corneum, thus helping to restore the skin's protective barrier.
Panthenol: thanks to its properties it is able to allow a correct level of skin hydration while keeping the skin elastic and hydrated. It also contributes to the skin's regeneration processes by providing protection from external aggressions.
Humectants (eg glycerin): moisturize the skin, binding and retaining water inside the stratum corneum.
Format
20g tube
It is a medical device. Read the warnings. Ministerial authorization of 17/04/2018.